# Research Peptide FAQ — Semaglutide, Tirzepatide, Tesamorelin, Retatrutide, BPC-157 — Prime Research Peptides > Frequently asked questions about five research peptides answered from the peer-reviewed literature: semaglutide, tirzepatide, tesamorelin, retatrutide, and BPC-157. Plain-English answers anchored to peer-reviewed citations — no speculation, no marketing, no human dosing advice. ## What is semaglutide? Semaglutide is a synthetic 31-amino-acid peptide analogue of the human incretin hormone GLP-1 (glucagon-like peptide-1). Two backbone substitutions make it resistant to the enzyme that degrades native GLP-1, and a fatty-acid side chain extends its half-life to roughly one week — which is why it can be dosed once weekly. It was approved by the FDA for type 2 diabetes and, subsequently, for chronic weight management and cardiovascular risk reduction in obesity. The 2023 SELECT trial in 17,604 adults established a 20% relative reduction in major adverse cardiovascular events [3]. ## What is semaglutide used for? FDA-approved indications include type 2 diabetes mellitus, chronic weight management in adults with obesity or overweight, reduction of cardiovascular events in adults with established CVD plus overweight/obesity, and (2025) metabolic dysfunction-associated steatohepatitis (MASH). The STEP 1 trial showed a mean -14.9% body weight versus -2.4% with placebo over 68 weeks [4]; the FLOW trial showed a 24% lower risk of major kidney-disease events in people with type 2 diabetes and chronic kidney disease [2]. This site summarizes approved-label and published-trial information and does not advise on prescribing. ## How does semaglutide work? By activating the GLP-1 receptor, semaglutide drives glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release from alpha cells, and slows gastric emptying. Its weight effect is primarily central: rodent studies showed it accesses the hypothalamic arcuate nucleus and brainstem area postrema, activating appetite-suppressing POMC/CART neurons and inhibiting appetite-stimulating NPY/AgRP neurons, reducing food intake without lowering energy expenditure [6]. The peripheral and central mechanisms together produce the glycemic and weight outcomes documented in large trials. ## How does semaglutide work for weight loss? The dominant mechanism for weight loss is appetite suppression through central GLP-1 receptor signaling. Brain-imaging and rodent-circuit studies show the drug quieting the brain circuits that drive food-seeking and caloric intake — not by accelerating calorie burning [6]. Gastric slowing contributes through earlier satiety. The scale of effect in the STEP program (-14.9% mean body weight in STEP 1) reflects both reduced energy intake and the attendant metabolic improvements that come with sustained weight reduction. The SURMOUNT-5 head-to-head trial found tirzepatide produced greater weight loss than semaglutide (-20.2% vs -13.7% at 72 weeks) [1]. ## What is tirzepatide? Tirzepatide is a 39-amino-acid synthetic peptide that agonizes both the GIP receptor and the GLP-1 receptor simultaneously — making it the first approved dual incretin agonist, sometimes called a "twincretin." It is FDA-approved for type 2 diabetes and, later, for chronic weight management and sleep apnea in obesity. Its dual-receptor engagement produces larger glycemic and weight effects in trials than selective GLP-1 agonists alone — a difference confirmed head-to-head in SURMOUNT-5 [1] and SURPASS-2 [11]. ## How does tirzepatide work? By engaging both the GIP and GLP-1 receptors, tirzepatide produces the full incretin effect of GLP-1 agonism — glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression — plus the additional insulin-sensitizing and potentially appetite-modulating effects of GIP receptor activation. The combination is additive: in SURPASS-2, tirzepatide reduced HbA1c by 2.30 percentage points versus 1.86 for semaglutide 1 mg at 40 weeks, and produced greater weight reduction at all doses [11]. The StatPearls clinical-reference chapter confirms the FDA-approved dual GLP-1/GIP mechanism [8]. ## What does tirzepatide do in the body? The glucose effects track the incretin mechanism: enhanced insulin secretion in the presence of glucose, suppressed glucagon, and modestly slower gastric emptying. The weight effects are primarily central appetite suppression amplified by the GIP arm. SURMOUNT-1 showed -20.9% mean body weight at the 15 mg dose versus -3.1% with placebo over 72 weeks in adults without diabetes [10]. Gastrointestinal effects (nausea, vomiting, constipation) are the dominant adverse event profile, emerging mainly during dose escalation. A meta-analysis found a significantly increased composite risk of gallbladder or biliary disease [9]. ## What is tirzepatide used for? FDA-approved uses include type 2 diabetes mellitus (first approval, 2022), chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. The compound was studied head-to-head against semaglutide in the SURMOUNT-5 trial and produced superior weight loss outcomes [1]. This desk describes published trial data using the international nonproprietary name tirzepatide only and does not promote any specific brand or sourcing. ## What is tesamorelin? Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), with an N-terminal trans-3-hexenoic acid group that extends plasma stability by blocking the enzyme that degrades native GHRH. It was FDA-approved in 2010 to reduce excess abdominal fat in HIV-infected adults with lipodystrophy — a specific complication of long-term antiretroviral therapy. A 2026 meta-analysis of five RCTs in HIV-associated lipodystrophy confirmed reduced visceral fat (-27.71 cm2), trunk fat, and hepatic fat while increasing lean mass [12]. Its FDA approval does not extend to any other indication. ## What does tesamorelin do? By binding the GHRH receptor on anterior-pituitary somatotroph cells, tesamorelin stimulates the body's own pulsatile growth hormone release. The resulting GH drives liver production of IGF-1, and GH plus IGF-1 together promote lipolysis preferentially in visceral adipose tissue. Because it amplifies endogenous GH rhythm rather than supplying exogenous GH, its metabolic profile differs from recombinant growth hormone. A 52-week HIV trial showed sustained -18% visceral fat at 52 weeks; fat reaccumulated after stopping [16]. The NIH LiverTox database assigns it a likelihood score of E — unlikely cause of liver injury [13]. ## How does tesamorelin work? It activates the GHRH receptor (Gs-coupled) on pituitary somatotrophs, triggering the adenylyl-cyclase/cAMP/PKA cascade that drives GH synthesis and secretion. In 13 healthy men, two weeks of tesamorelin increased mean overnight GH (+0.5 ug/L, P=0.004) and raised IGF-1 by 181 ug/L (P<0.0001), while neither fasting glucose nor insulin sensitivity was significantly affected [15] — a clean GH-axis signal without the glucose perturbations common with exogenous GH. The practical downstream effect is selective visceral lipolysis, particularly in the HIV-lipodystrophy setting where excess visceral fat accumulates on antiretrovirals. ## Will tesamorelin help me lose belly fat? It reduced visceral abdominal fat in HIV-positive adults with lipodystrophy — a specific population, a specific metabolic problem — and that is what the FDA approved it for. Whether it reduces visceral fat in people without HIV lipodystrophy is mechanistically plausible (the GHRH axis operates in everyone) but not established by large controlled trials in that population. The off-label use is investigational. The important caveat in even the HIV data: visceral fat reaccumulated within weeks of stopping treatment [16], which frames tesamorelin as a continuous rather than curative intervention. ## Is retatrutide FDA approved? No. As of mid-2026, retatrutide (LY3437943) has no regulatory approval from the FDA or any other agency. It is in Phase 3 clinical trials (the TRIUMPH program). Its efficacy data — including -24.2% body weight in a Phase 2 obesity trial at 12 mg [20] and -16.94% in a Phase 2 type 2 diabetes trial [21] — come from trials, not from an approved product. Material sold outside those clinical trials cannot be verified for identity, purity, or sterility. ## How does retatrutide work? Retatrutide agonizes three receptors simultaneously: GLP-1R, GIPR, and the glucagon receptor (GCGR). The GLP-1 and GIP arms suppress appetite and improve glucose-dependent insulin secretion; the glucagon arm adds energy expenditure and lipid mobilization. Cryo-EM structural work confirmed triple-receptor engagement and quantified relative potency: approximately 8.9x the potency of native GIP at GIPR, 0.3x at GCGR, 0.4x at GLP-1R versus native hormones [18]. The glucagon component is also the mechanism behind the dose-dependent heart-rate increases observed in Phase 2, peaking around 24 weeks [20]. ## What does retatrutide do? In Phase 2 trials, the most conspicuous effects were profound weight reduction (up to -24.2% at 12 mg over 48 weeks versus -2.1% placebo) [20], large HbA1c reductions in people with type 2 diabetes (-2.02% at 12 mg) [21], and dramatic liver-fat reduction in people with MASLD (-82.4% relative liver-fat change at 12 mg at 24 weeks, with 86% reaching normal liver fat) [19]. The adverse-effect pattern is GI-dominant — nausea, constipation, diarrhea — similar to the GLP-1 class, plus the heart-rate signal from glucagon receptor engagement. ## What does BPC-157 do in the body? In animal models — predominantly rats — BPC-157 is described as a cytoprotective and regenerative peptide whose effects are tied most consistently to angiogenesis. The best-characterized pathway is up-regulation and internalization of the VEGFR2 receptor with downstream VEGFR2-Akt-eNOS signaling; blocking that internalization blocked the pro-angiogenic effect in vascular models [25]. Animal studies have shown effects on gastric-ulcer healing, tendon repair, and gut protection. In humans, the evidence is extremely limited: a 2025 review identified only three pilot studies and zero large rigorous trials [23]. ## Is BPC-157 a growth hormone? No. BPC-157 is a synthetic fifteen-amino-acid peptide derived from a protein in gastric juice — it is not growth hormone and not a growth-hormone secretagogue in the established sense. The connection sometimes cited is that BPC-157 has been reported in animal work to sensitize the growth-hormone receptor in tendon fibroblasts — meaning it may amplify the effect of the body's own GH in that tissue context. Sensitizing a receptor is not the same as being growth hormone or replacing it. ## Does BPC-157 work immediately? The compound clears from the bloodstream quickly. First pharmacokinetic work in rats and beagle dogs found an elimination half-life under 30 minutes, with modest intramuscular bioavailability and rapid breakdown into small fragments that re-enter normal amino-acid metabolism [24]. An immediate pharmacokinetic effect is therefore unlikely, and any tissue-level healing effects observed in animal studies were measured over days to weeks, not acutely. This site does not advise on timing or use. ## Does BPC-157 damage the liver? The available data do not demonstrate liver harm, but those data are very thin. The 2025 first-in-human IV safety pilot gave BPC-157 to two healthy adults and found no measurable changes in hepatic biomarkers and no adverse events [22]. That is reassuring, and two-person safety pilots cannot establish a drug's safety profile. A 2025 narrative review explicitly states that the human evidence is limited to only three small pilots and that rigorous large-scale trials are lacking [23]. The honest answer is that the human liver-safety profile of BPC-157 is not established. --- An independent literature desk mapping the evidence from regulatory approval to first-in-human pilot — a spectrum, not a sales pitch.